Participation in the Lung Adjuvant Cisplatin Evaluation Biological Program (LACE-BIO). A Study of Prognostic and Predictive Markers in Early Stage Non-Small Cell Lung Cancer
- To evaluate potential prognostic and predictive markers in patients treated with
adjuvant chemotherapy for early-stage non-small cell lung cancer.
- To perform cross-validation analyses for the predictive value of p27, ERCC1, and
- To perform cross-validation analyses for the prognostic value of mucin and BRCA1
- To perform a pooled analysis for the prognostic impact of p53 protein expression by
IHC, p53 mutation, ras mutation, and EGFR mutation.
OUTLINE: This is a multicenter study. Patients are stratified according to planned
radiotherapy (yes vs no), area of the world (Eastern Europe vs Western Europe vs rest of the
world), and center size (< 20 vs > 20 patients).
Tumor tissue samples are selected from CALGB-9633 and from Lung Adjuvant Cisplatin
Evaluation (LACE) group's studies; ANITA, FRE-IALT, and CAN-NCIC-BR10. Clinical data are
gathered from these patients' protocol records and sent to Institute Gustave-Roussy for
cross-validation studies and pooled analyses.
Tissue samples are analyzed by IHC to identify predictive markers and investigate protein
expression and mutations and by Cox model for prognostic values.
Stephen L. Graziano, MD
State University of New York - Upstate Medical University
United States: Federal Government